Connect Biopharma Holdings Limited Ordinary Shares (CNTB)
Stock · NASDAQ · Health Care
$0.8876as of 10/16/2026
Price chart
Active signals
CNTB Signal Track Record
How signals performed across all stocks →What CNTB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | -2.6% | 43% | September 30, 2026 |
| Bollinger Band Breakout | 27 | -9.2% | 33% | September 2, 2026 |
| 200-Day Moving Average TouchActive now | 19 | +5.7% | 63% | August 18, 2026 |
| Bollinger Band Breakdown | 17 | -1.7% | 47% | September 3, 2026 |
| Any 20-session window (baseline) | -0.9% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CNTB
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 64
- Website
- www.connectbiopharm.com
Fundamentals
- 1-day range
- $0.87$0.9085
- Market cap
- $137.89M
- P/E (trailing)
- —
- P/E (forward)
- -1.17
- EPS (trailing)
- $-1.20
- Dividend yield
- —
- Beta
- -0.08
- Avg. volume
- 3.88M
How Connect Biopharma Holdings Limited Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 31, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Connect Biopharma Holdings Limited Ordinary Shares Competitors
Chosen by industry and closest market cap.
- CNTBConnect Biopharma Holdings Limited Ordinary Shares$0.906▲ 0.00%Market cap $137.89MP/E —$0.8501$3.82
- UNCYUnicycive Therapeutics Inc. Common Stock$3.36▼ 6.41%Market cap $138.33MP/E —$3.56$8.74
- OGIOrganigram Global Inc. Common Shares$0.927▼ 0.54%Market cap $139.37MP/E 2.08$1.2$3.09
- VTVTvTv Therapeutics Inc. Class A Common Stock$26.54▼ 3.81%Market cap $136.33MP/E 55.59$19.5$44
- KZIAKazia Therapeutics Limited American Depositary Shares$7.25▼ 2.03%Market cap $140.89MP/E —$4.86$17.4
- HURATuHURA Biosciences Inc. Common Stock$1.76▼ 3.83%Market cap $134.69MP/E —$0.41$3.43
- NGENNervGen Pharma Corp. Common stock$1.59▼ 1.85%Market cap $141.37MP/E —$3.2$8.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings Limited Ordinary Shares | $137.89M | — | $0.906 | ▲ 0.00% | $0.8501$3.82 |
| UNCY Unicycive Therapeutics Inc. Common Stock | $138.33M | — | $3.36 | ▼ 6.41% | $3.56$8.74 |
| OGI Organigram Global Inc. Common Shares | $139.37M | 2.08 | $0.927 | ▼ 0.54% | $1.2$3.09 |
| VTVT vTv Therapeutics Inc. Class A Common Stock | $136.33M | 55.59 | $26.54 | ▼ 3.81% | $19.5$44 |
| KZIA Kazia Therapeutics Limited American Depositary Shares | $140.89M | — | $7.25 | ▼ 2.03% | $4.86$17.4 |
| HURA TuHURA Biosciences Inc. Common Stock | $134.69M | — | $1.76 | ▼ 3.83% | $0.41$3.43 |
| NGEN NervGen Pharma Corp. Common stock | $141.37M | — | $1.59 | ▼ 1.85% | $3.2$8.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Leerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4benzinga · 10/12/2026
- HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price TargetBenzinga · 10/8/2026
- Connect Biopharma COPD Study Shows 81% Cut in Treatment FailuresYahoo · 10/4/2026
- HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price TargetBenzinga · 10/2/2026
- Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session.ChartMill · 9/30/2026
- Discover the most active stocks in Wednesday's session.ChartMill · 9/30/2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · 9/30/2026
- Let's take a look at the stocks that are in motion in today's session.ChartMill · 9/30/2026
- Crude Oil Rises Over 1%; Conagra Brands Earnings Top ViewsBenzinga · 9/30/2026
Insider Activity
Insider Actions →- Kleanthis Gabriel Xanthopoulos · September 30, 2026 · Grant5.0K
- Jean I. Liu · September 30, 2026 · Grant9.0K
- Kleanthis Gabriel Xanthopoulos · June 30, 2026 · Grant3.7K
- Jean I. Liu · June 30, 2026 · Grant6.7K
- James Huang · May 29, 2026 · Buy150.0K @ $2.48
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CNTB Misses Asthma Trial Goal as Oppenheimer Lowers Target
Connect Biopharma reported that its latest asthma trial did not meet the primary endpoint. The result may affect the progression of the drug program. Oppenheimer kept an Outperform rating but reduced its price target to $5, below the consensus $6.50. The stock is currently trading near its recent support level.
CNTB Misses Asthma Trial Goal as Oppenheimer Lowers Target. Connect Biopharma reported that its latest asthma trial did not meet the primary endpoint. The result may affect the progression of the drug program. Oppenheimer kept an Outperform rating but reduced its price target to $5, below the consensus $6.50. The stock is currently trading near its recent support level.